Strides Pharma Science Limited (NSE:STAR)
India · Delayed Price · Currency is INR | Market Cap | 106.63B +77.2% |
| Revenue (ttm) | 47.26B +3.2% |
| Net Income | 5.11B -85.5% |
| EPS | 55.49 -85.5% |
| Shares Out | 92.17M |
| PE Ratio | 20.85 |
| Forward PE | 16.87 |
| Dividend | 4.00 (0.35%) |
| Ex-Dividend Date | Jul 22, 2025 |
| Volume | 142,455 |
| Average Volume | 297,951 |
| Open | 1,156.90 |
| Previous Close | 1,156.90 |
| Day's Range | 1,145.20 - 1,177.00 |
| 52-Week Range | 639.20 - 1,175.00 |
| Beta | 0.31 |
| RSI | 76.11 |
| Earnings Date | May 22, 2026 |
About Strides Pharma Science
Strides Pharma Science Limited develops, manufactures, and sells pharmaceutical products in Africa, Australia, North America, Europe, Asia, and internationally. The company offers pharma generics in various forms, such as tablets, hard and soft gelatin capsules, sachets, and liquids, as well as nasal spray, gels, powders, solids, ointments, and creams. It also develops branded generics products for the treatment of chronic therapies, including women’s health, central nervous system, cardiovascular, diabetes, dermatology, and probiotics under th... [Read more]
Financial Performance
Financial StatementsNews
Pharma stocks surge today, April 23: Dr. Reddy's Lab gains 6.43%, Strides Pharma rises 5.01%, Orchid Pharma surges 5.77%
Shares of pharmaceutical sector companies traded broadly higher on April 23, 2026, with Dr. Reddy's Laboratories, Strides Pharma Science, Orchid Pharma, and Glenmark Pharma among the standout gainers,...
Strides Pharma shares over 3% after acquiring generic brands from Sandoz for US$ 12 million
Strides Pharma Science shares gained over 3% after the company announced a strategic acquisition aimed at expanding its footprint in the Sub-Saharan Africa (SSA) region. As of 9:38 AM, the…
Strides Pharma Science acquires generic brands from Sandoz for US$ 12 million
Strides Pharma Science Limited has announced a strategic acquisition to bolster its presence in the Sub-Saharan Africa (SSA) region. The company, through its step-down subsidiary Strides Pharma Intern...
Strides Pharma Science Ltd (BOM:532531) Q3 2026 Earnings Call Highlights: Record EBITDA and ...
Strides Pharma Science Ltd (BOM:532531) Q3 2026 Earnings Call Highlights: Record EBITDA and Strategic Diversification Drive Growth
Q3 2026 Strides Pharma Science Ltd Earnings Call Transcript
Q3 2026 Strides Pharma Science Ltd Earnings Call Transcript
Strides Pharma Science Transcript: Q3 25/26
Gross margins and profitability improved, with EBITDA and PAT showing strong year-on-year growth. Ex-U.S. markets drove revenue expansion, while U.S. business remained flat due to seasonal and competitive factors. Balance sheet metrics and operational cash flow strengthened.
Strides Pharma Science shares jump over 4% after Q3 profit surges 130% YoY to Rs 202 crore
Shares of Strides Pharma Science climbed more than 4% on the NSE on Thursday, reacting positively to the company’s strong...
Strides Pharma Q3 Results: Net profit surges 130% YoY to Rs 202 crore, revenue up 3.6%
Strides Pharma Science reported a strong set of financial results for the third quarter, delivering sharp growth in profitability and...
Strides Pharma Science Ltd (BOM:532531) Q2 2026 Earnings Call Highlights: Strong Revenue Growth ...
Strides Pharma Science Ltd (BOM:532531) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Market Positioning
Q2 2026 Strides Pharma Science Ltd Earnings Call Transcript
Q2 2026 Strides Pharma Science Ltd Earnings Call Transcript
Strides Pharma Science Transcript: Q2 25/26
Q2 and H1 FY26 delivered strong growth in revenue, margins, and profitability, driven by disciplined execution, operating leverage, and a focus on sustainable, long-term growth. U.S. and other regulated markets showed steady performance, with robust cash flow and debt reduction.
Strides Pharma Science Transcript: Q1 25/26
Strong quarterly results with revenue of INR 11.2 billion, 19.5% EBITDA margin, and 81% EPS growth year-on-year. U.S. and growth markets performed well, while access markets faced funding challenges. Long-term U.S. sales guidance of $400 million by FY2028 remains intact.
Strides Pharma shares hit 52-week high, jumps 3% after Q1 PAT jumps 81% YoY
Shares of Strides Pharma Science Ltd surged over 3% on July 29, hitting a fresh 52-week high of ₹968 on the NSE after the company reported robust Q1FY26 earnings. The stock was last seen trading at ₹9...
Strides Pharma Q1 Results: Revenue rises 6.2% YoY to Rs 1119 crore, Net Profit at Rs 105.6 crore
Strides Pharma Science Ltd reported a strong performance for the quarter ended June 30, 2025, with revenue from operations rising 6.2% YoY to ₹1119.7 crore. The company’s operational profit after tax ...
Strides Pharma Science Transcript: Q4 24/25
FY25 saw robust revenue and EBITDA growth, with US business outperforming and margins expanding. Debt reduction, strong cash flow, and increased R&D investment position the company for continued growth, with a focus on high-value US launches and stable margins.
Strides Pharma receives USFDA approval for Celecoxib Capsules
Strides Pharma Science Limited announced that its stepdown wholly owned subsidiary, Strides Pharma Global Pte. Limited, based in Singapore, has received approval from the United States Food & Drug Adm...
Strides Pharma incorporates new subsidiary ‘Pivot Path’ to boost life sciences and digital innovation
Strides Pharma Science Limited has announced the incorporation of a new step-down wholly owned subsidiary named Pivot Path Private Limited through its subsidiary Arco Lab Private Limited. The new enti...
Strides Pharma Science Transcript: Q3 24/25
Strong Q3 and nine-month results driven by robust US and growth/access markets, margin expansion, and successful soft-gelatin business demerger. Guidance for FY25 and FY28 remains on track, with focus on debt reduction, R&D, and new product launches.
Strides Pharma shares surge 5% as revenue jumps 15% YoY in Q3 FY25
Strides Pharma Science Limited’s shares rose 5% following the release of its Q3 FY25 financial results, showcasing robust year-on-year (YoY) growth and a strong profit recovery. As of 1:43 PM, the sha...
Strides Pharma Q3 FY25 Results: Revenue up 15% YoY to Rs 1,154 crore, Net Profit up 60% YoY
Strides Pharma Science Limited reported its Q3 FY25 financial performance with strong year-on-year (YoY) revenue growth and a significant improvement in net profit. The company’s revenue from operatio...
Strides Pharma receives USFDA approval for acetaminophen and ibuprofen tablets, expanding OTC portfolio
Strides Pharma Science Limited has announced a significant milestone with USFDA approval for acetaminophen and ibuprofen tablets, 125 mg/250 mg. This development is set to enhance the company’s over-t...
Strides Pharma Science Transcript: Q2 24/25
Strong quarterly results with 17% revenue growth, record EBITDA, and improved margins. U.S. and softgel segments outperformed, while guidance was raised to the higher end for FY25. OneSource capacity is fully booked, with robust order book and margin expansion expected.
Strides Pharma Science Q2 FY25 Results: Net profit surges to ₹93.7 crore, US revenues hit historic high
Bangalore, India, October 24, 2024 – Strides Pharma Science Ltd (BSE: 532531, NSE: STAR) has announced impressive financial results for the second quarter of FY25, showcasing significant year-on-year ...
OneSource raises Rs 801 crore from investors, boosts growth for Strides shareholders
Strides Pharma Science’s associate company, OneSource Specialty Pharma, has successfully raised INR 801 crore (approximately USD 95 million) from marquee investors at a pre-money valuation of USD 1.65...
Strides Pharma shares surge 3% on USFDA nod for Fluoxetine Tabs 60 mg
Shares of Strides Pharma Science Ltd. jumped 3% after the company announced that its subsidiary, Strides Pharma Global Pte. Limited, Singapore, received USFDA approval for Fluoxetine Tablets 60 mg. Wi...